✦ LIBER ✦

Coronary heart disease in women: Hormone replacement therapy

✍ Scribed by Mary S. Beattie; Rita Redberg

Publisher: Springer
Year: 2002
Tongue: English
Weight: 303 KB
Volume: 4
Category: Article
ISSN: 1092-8464
DOI: 10.1007/s11936-002-0033-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A story of evidence-based medicine: Horm

A story of evidence-based medicine: Hormone replacement therapy and coronary heart disease in postmenopausal women

✍ Arlene S. Swern 📂 Article 📅 2010 🏛 American Statistical Association ⚖ 487 KB

Hormone replacement therapy for preventi

Hormone replacement therapy for prevention of coronary heart disease: Current evidence

✍ P. Sheena Khurana; Charanjit Khurana; Judith Hsia 📂 Article 📅 2001 🏛 Current Science Inc. 🌐 English ⚖ 237 KB

Brief Report: Coronary Heart Disease Eve

Brief Report: Coronary Heart Disease Events Associated with Hormone Therapy in Younger and Older Women

✍ Shelley R. Salpeter; Judith M. E. Walsh; Elizabeth Greyber; Edwin E. Salpeter 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

Hormone replacement therapy for primary

Hormone replacement therapy for primary and secondary prevention of heart disease

✍ Svati H. Shah; Karen P. Alexander 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 407 KB

Changes in bone density in women startin

Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy

✍ B. Lees; M. Pugh; N. Siddle; J. C. Stevenson 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 579 KB

Risk of cancer in women receiving hormon

Risk of cancer in women receiving hormone replacement therapy

✍ Hans-Olov Adami; Ingemar Persson; Robert Hoover; Catharine Schairer; Leif Bergkv 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 828 KB

Cancer risk following treatment with non-contraceptive estrogens was studied in a population-based cohort of 23,244 women. Complete follow-up for an average of 6.7 years revealed 1,087 incident cancers versus 962.5 expected (relative risk/RR/ = 1.13; 95% confidence interval 1.10-1.20). We confirmed